{"protocolSection":{"identificationModule":{"nctId":"NCT03995524","orgStudyIdInfo":{"id":"F-FR-52120-258"},"organization":{"fullName":"Ipsen","class":"INDUSTRY"},"briefTitle":"Spasticity and Treatment Satisfaction Among Stroke Survivors","officialTitle":"Perceived Spasticity and Treatment Satisfaction Among Stroke Survivors Over the Course of a Complete Treatment Cycle With Botulinum Neurotoxin A (BoNT-A): an Ethnographic Study.","acronym":"REBOT"},"statusModule":{"statusVerifiedDate":"2020-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-07-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-05-12","type":"ACTUAL"},"completionDateStruct":{"date":"2020-05-12","type":"ACTUAL"},"studyFirstSubmitDate":"2019-05-29","studyFirstSubmitQcDate":"2019-06-19","studyFirstPostDateStruct":{"date":"2019-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-05-29","lastUpdatePostDateStruct":{"date":"2020-06-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ipsen","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To investigate, through ethnography, changes in symptom burden and disability and their effects/interference on patient functioning, ability to perform activities of daily living (ADL) and quality of life (QoL) throughout the duration of one BoNT-A treatment cycle."},"conditionsModule":{"conditions":["Spasticity as Sequela of Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":30,"type":"ACTUAL"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Degree of functional limitations in daily life activities","description":"Degree of functional limitations in daily life activities (i.e. physical functioning) associated with post-stroke spasticity as assessed by using WHODAS parameters, and identification of their characteristics and changes over time","timeFrame":"monthly for 12 Weeks, or until end of injection cycle whichever occurs first"},{"measure":"Health status in subjects with post-stroke spasticity","description":"Health status in subjects with post-stroke spasticity as assessed by using EQ-5D-5L parameters, and identification of their characteristics and changes over time","timeFrame":"weekly for 12 Weeks, or until end of injection cycle whichever occurs first"},{"measure":"Severity of Pain","description":"Severity of Pain as per EQ-5D-5L and a sliding scale. This is a descriptive scale that covers 5 dimensions: mobility, self-care, usual activities,pain/discomfort and anxiety/depression. the scale consist of 5 levels, where level one corresponds to \"no problems\" and level 5 corresponds to \"extreme problem\".","timeFrame":"12 weeks"}],"secondaryOutcomes":[{"measure":"Burden of spasticity/treatment","description":"Themes/domains related to the everyday life experiences of subjects with post-stroke spasticity (e.g. burden disease/treatment) through qualitative analysis of in-depth open-ended interviews","timeFrame":"Opening interview and ending qualitative interviews, ethnography data which will be provided at discretion of patient/caregiver for 12 weeks or duration of treatment, whichever occurs first, may also support these qualitative analyses"},{"measure":"Patients' satisfaction","description":"Subjects Report of Satisfaction with Treatment and their perception/desire of more tailored treatment options","timeFrame":"weekly for 12 weeks or until end of injection cycle whichever occurs first. Opening and closing interview will also explore this"},{"measure":"Comparison of feedback between caregivers and stroke survivors","description":"Agreement between the themes elicited from semi-structured interviews between caregivers and subjects","timeFrame":"opening ( before week 1) and ending ( 2 weeks after end of injection cycle) qualitative interviews"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnostic of post-stroke spasticity more than three months prior to inclusion\n* At least 6 months on treatment (or two treatment cycles) with BoNT-A injections for spasticity according to the decision of the physician\n* Previous BoNT-A injection cycles did not last for more than 16 weeks\n* Ambulatory (use of walking aids is acceptable)\n\nExclusion Criteria:\n\n* Neurological disorder other than stroke\n* Spasticity-specific treatment changes within 3 months prior to inclusion\n* Patients who had undergone neurolysis or surgery to the affected limb within 6 months\n* Concurrent participation in a clinical trial for the treatment of spasticity","sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"40 Adults subjects (male or female) suffering from post-stroke spasticity (the US, UK, France, and Italy), who are treated with BoNT-A in the course of routine clinical practice for focal spasticity","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Ipsen Medical Director","affiliation":"Ipsen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Ipsen Central Contact","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","relevance":"LOW"},{"id":"M250157","name":"abobotulinumtoxinA","relevance":"LOW"},{"id":"M20947","name":"Botulinum Toxins, Type A","relevance":"LOW"},{"id":"M250251","name":"incobotulinumtoxinA","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}